Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.

Ji, Hong-Long; Wagener, Brant M; Ness, Timothy J; Zhao, Runzhen

Ji, Hong-Long; Wagener, Brant M; Ness, Timothy J; Zhao, Runzhen.

Ji HL; Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA; Texas Lung Injury Institute, The University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA. Electronic address: james.ji@uthct.edu.
Wagener BM; Division of Molecular and Translational Biomedicine, USA; Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: bwagener@uabmc.edu.
Ness TJ; Division of Molecular and Translational Biomedicine, USA. Electronic address: tness@uabmc.edu.
Zhao R; Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA. Electronic address: Zhao@uthct.edu.

Pulm Pharmacol Ther ; 70: 102055, 2021 10.

Article in English | MEDLINE | ID: covidwho-1316613

Subject(s)

Benzamidines/therapeutic use; COVID-19 Drug Treatment; Fibrinolysin; Guanidines/therapeutic use; Fibrinolysin/therapeutic use; Humans

Keywords

Anti-Protease; COVID-19; Fibrinolytic therapy; Plasmin

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzamidines / Fibrinolysin / COVID-19 Drug Treatment / Guanidines Limits: Humans Language: English Journal: Pulm Pharmacol Ther Journal subject: Pharmacology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google